Vertex Shares Promising 48-Week Results for Povetacicept, Originally Developed by Alpine Immune Sciences

Vertex released encouraging 48-week data for povetacicept, its investigational treatment for two autoimmune kidney diseases, IgA nephropathy and primary membranous nephropathy. The therapy, initially developed by Seattle-based Alpine Immune Sciences, led to large drops in urine protein, stable kidney function, and meaningful remission rates. The drug was generally well tolerated with mostly mild side effects.